Related references
Note: Only part of the references are listed.MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Stefan S. Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications
Surabhi Parashar et al.
CANCER MEDICINE (2015)
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
L. Zhou et al.
LEUKEMIA (2015)
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
Lei Zhang et al.
MEDICINAL RESEARCH REVIEWS (2015)
Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line
Enrico Capobianco et al.
PLOS ONE (2014)
Advances in Therapy for Pediatric Sarcomas
Aaron Weiss et al.
CURRENT ONCOLOGY REPORTS (2014)
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Xiang Chen et al.
CELL REPORTS (2014)
Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells
Xiucheng Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
A Proposal Regarding Reporting of In Vitro Testing Results
Malcolm A. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group
Robert E. Goldsby et al.
EUROPEAN JOURNAL OF CANCER (2013)
Future of Clinical Genomics in Pediatric Oncology
Katherine A. Janeway et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis
Marnie Collins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro
Zhiyuan Lou et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Andrea Newbold et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)
Jodi A. Muscal et al.
PEDIATRIC BLOOD & CANCER (2013)
Children's Oncology Group's 2013 blueprint for research: Bone tumors
Richard Gorlick et al.
PEDIATRIC BLOOD & CANCER (2013)
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program
E. Anders Kolb et al.
PEDIATRIC BLOOD & CANCER (2013)
Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas
Jenny M. Kreahling et al.
PLOS ONE (2013)
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor
W. Fu et al.
CELL DEATH & DISEASE (2013)
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
J. E. Bolden et al.
CELL DEATH & DISEASE (2013)
A review of targeted therapies evaluated by the pediatr preclinical testing program for osteosarcoma
Valerie B. Sampson et al.
FRONTIERS IN ONCOLOGY (2013)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Outcome for adolescent and young adult patients with osteosarcoma
Katherine A. Janeway et al.
CANCER (2012)
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Alexei F. Kisselev et al.
CHEMISTRY & BIOLOGY (2012)
A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma
Luke A. Wittenburg et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
David Ebb et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells
Jenny M. Kreahling et al.
MOLECULAR CANCER THERAPEUTICS (2012)
H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes
Kiran Mahajan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program
Richard B. Lock et al.
PEDIATRIC BLOOD & CANCER (2012)
Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines
Venugopal Thayanithy et al.
PLOS ONE (2012)
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Simon J. Harrison et al.
BLOOD (2011)
Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor
Sushil Kumar et al.
CLINICAL CANCER RESEARCH (2011)
Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease
Raquel Dominguez-Kelly et al.
JOURNAL OF CELL BIOLOGY (2011)
The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
Wei Fu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi et al.
BLOOD (2010)
Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Shana Jacobs et al.
CLINICAL CANCER RESEARCH (2010)
Animal models of osteosarcoma
Timothy M. Fan
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma
Yuriy Shapovalov et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone
Heng Zhu et al.
NATURE PROTOCOLS (2010)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Quantifying synergism/antagonism using nonlinear mixed-effects modeling: A simulation study
John C. Boik et al.
STATISTICS IN MEDICINE (2008)
Histone deacetylase inhibitors: Overview and perspectives
Milos Dokmanovic et al.
MOLECULAR CANCER RESEARCH (2007)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models
JK Peterson et al.
CLINICAL CANCER RESEARCH (2005)
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
